WARSAW,
Ind., June 20, 2024 /PRNewswire/ -- Zimmer
Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical
technology leader, today announced that Devdatt "Dev" Kurdikar,
President, Chief Executive Officer and a member of the board of
directors of Embecta Corp. (embecta), has been appointed to the
Zimmer Biomet Board, effective immediately. embecta (Nasdaq: EMBC),
formerly part of Becton, Dickinson and Company (BD), is one of the
largest pure-play diabetes management companies in the
world.
"We are pleased to welcome Dev to the ZB Board,"
said Chris Begley, Chairman of the Company's Board of
Directors. "Dev brings a wealth of medtech, innovation and
leadership experience that will be invaluable to ZB as we further
advance our strategic priorities and mission to alleviate pain and
improve peoples' lives."
Mr. Kurdikar has served as the President and Chief Executive
Officer and a member of the board of directors of embecta since its
spinoff from BD on April 1, 2022.
He was the Worldwide President of Diabetes Care at BD from
2021 until the spinoff. Prior to joining BD, Mr. Kurdikar was
President and CEO of Cardiac Science Corporation (CSC) from 2016 to
2019. Prior to that role, Mr. Kurdikar was the Vice President
and General Manager, Men's Health, within Urology and Pelvic Health
at Boston Scientific Corporation (Boston Scientific) from 2015 to
2016. Mr. Kurdikar served in the same role at American
Medical Systems (AMS) starting in 2013 and led the Men's Health
business through its carve-out, sale and integration into Boston
Scientific. Before joining AMS, Mr. Kurdikar worked for 11 years
with Baxter International, Inc., holding leadership roles of
increasing responsibility in finance, strategy and integration,
R&D planning and operations, ultimately serving as Vice
President, Marketing, from 2011 through 2013. He began his
career as a Senior Research Engineer at The Monsanto Company.
Mr. Kurdikar holds a Bachelor in Chemical Engineering from the
University of Bombay (India). He earned a Master of Science in
Chemical Engineering from Washington State
University, a Ph.D. in Chemical Engineering from
Purdue University, and a Master of
Business Administration from Washington University. In
addition to serving on the embecta board, Mr. Kurdikar serves on
the board of directors of AdvaMed (the Advanced Medical Technology
Association).
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a
comprehensive portfolio designed to maximize mobility and improve
health. We seamlessly transform the patient experience through our
innovative products and suite of integrated digital and robotic
technologies that leverage data, data analytics and artificial
intelligence.
With 90+ years of trusted leadership and proven expertise,
Zimmer Biomet is positioned to deliver the highest quality
solutions to patients and providers. Our legacy continues to come
to life today through our progressive culture of evolution and
innovation.
For more information about our product portfolio, our operations
in 25+ countries and sales in 100+ countries or about joining our
team, visit www.zimmerbiomet.com or follow on LinkedIn at
www.linkedin.com/company/zimmerbiomet or X / Twitter at
www.twitter.com/zimmerbiomet.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include,
but are not limited to, statements concerning Zimmer Biomet's
expectations, plans, prospects, and product and service offerings.
Such statements are based upon the current beliefs and expectations
of management and are subject to significant risks, uncertainties
and changes in circumstances that could cause actual outcomes and
results to differ materially. For a list and description of some of
such risks and uncertainties, see Zimmer Biomet's periodic reports
filed with the U.S. Securities and Exchange Commission (SEC). These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in Zimmer Biomet's filings with the SEC. Forward-looking
statements speak only as of the date they are made, and Zimmer
Biomet disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise. Readers of this news
release are cautioned not to rely on these forward-looking
statements, since there can be no assurance that these
forward-looking statements will prove to be accurate. This
cautionary note is applicable to all forward-looking statements
contained in this news release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-appointment-of-devdatt-kurdikar-to-board-of-directors-302177446.html
SOURCE Zimmer Biomet Holdings, Inc.